This content is in French.
Lupus under control?
7 mai 2025
#Lupus #SLE #Baricitinib #JAK #Autoimmunity
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the aberrant production of autoantibodies and multisystem inflammation. Its clinical expression is heterogeneous and unpredictable, with acute flares alternating with remission phases, making management particularly complex. SLE predominantly affects women of childbearing age, raising specific issues related to fertility and obstetric care.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the aberrant production of autoantibodies and multisystem inflammation. Its clinical expression is heterogeneous and unpredictable, with acute flares alternating with remission phases, making management particularly complex. SLE predominantly affects women of childbearing age, raising specific issues related to fertility and obstetric care.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Yin, J., et al. (2025). Clinical outcomes of baricitinib in patients with systemic lupus erythematosus: Pooled analysis of SLE-BRAVE-I and SLE-BRAVE-II trials. PloS one, 20(4), e0320179
View the source
